<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04271579</url>
  </required_header>
  <id_info>
    <org_study_id>ProsTone-MK-2020</org_study_id>
    <secondary_id>DRKS00020130</secondary_id>
    <nct_id>NCT04271579</nct_id>
  </id_info>
  <brief_title>Early Prostate Cancer Recurrence With PSMA PET Positive Unilateral Pelvic Lesion(s)</brief_title>
  <acronym>ProsTone</acronym>
  <official_title>Early Prostate Cancer Recurrence With PSMA PET Positive Unilateral Pelvic Lesion(s): is One-sided Salvage Extended Lymph Node Dissection Enough</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Martini-Klinik am UKE GmbH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital Hamburg, Institute of Tumor Biology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Martini-Klinik am UKE GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Significant advances in molecular nuclear medicine imaging in prostate cancer have been&#xD;
      achieved in recent years. In particular, the introduction of prostate-specific membrane&#xD;
      antigen (PSMA) -based tracers has significantly influenced diagnostic imaging of prostate. If&#xD;
      cancer recurs after surgical removal of the prostate, targeted PSMA PET (positron emission&#xD;
      tomography) can detect metastases even at very low PSA (prostate-specific Antigen) values.&#xD;
      This increasingly allows individualized specific therapy of patients with prostate cancer&#xD;
      recurrence. PSMA PET has now been included in national and international guidelines for the&#xD;
      diagnosis of patients with biochemical recurrence of prostate cancer.&#xD;
&#xD;
      Especially in patients in good general condition, with potentially longer life expectancy and&#xD;
      early localized PSA recurrence, advances in molecular imaging are increasingly turning local&#xD;
      therapy concepts into focus. Here both, radiotherapeutic (salvage radiotherapy of the&#xD;
      lymphatic drainage) and surgical interventions (salvage lymph node dissection = removal of&#xD;
      the pelvic lymph nodes) are offered on an individual basis.&#xD;
&#xD;
      These regional therapies mainly aim to achieve a delay of further progression of the prostate&#xD;
      cancer disease, and thus delay the initiation of palliative, sustained drug therapy. Previous&#xD;
      standard or common practice at salvage lymph node dissection is the removal on both sides of&#xD;
      the pelvic lymph nodes even if only one-sided suspicious lymph nodes are detected on imaging.&#xD;
      Although the complications of salvage lymph node dissection are usually minor and manageable,&#xD;
      they can still lead to impaired lymphatic drainage, leg edema, lymphocele formation or other&#xD;
      surgical complications.&#xD;
&#xD;
      The aim of the present study is to investigate whether a unilateral pelvic lymph node&#xD;
      dissection on the side of conspicuous PSMA PET is sufficient and a dissection on the&#xD;
      contralateral side can be dispensed without negatively impacting oncological outcomes and&#xD;
      thereby sparing the patient the potential additional complications of a bilateral pelvic&#xD;
      lymph node dissection.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this prospective randomized study, patients with early biochemical recurrence after&#xD;
      radical prostatectomy and with PSMA-PET positive unilateral pelvic metastatic lesions are&#xD;
      assessed as to whether unilateral and bilateral salvage lymph node dissection are&#xD;
      oncologically equivalent. For this, the following endpoints will be evaluated:&#xD;
&#xD;
        -  complete biochemical response (cBR: PSA &lt;0.2ng /ml) after salvage lymph node dissection&#xD;
&#xD;
        -  biochemical freedom from recurrence without further prostate-cancer-specific therapy&#xD;
           (time from salvage lymph node dissection to first PSA value&gt; 0.2ng / ml)&#xD;
&#xD;
        -  prostate cancer-specific therapy-free time (time from salvage lymph node dissection to&#xD;
           initiation of prostate cancer specific therapy) In addition, the diagnostic accuracy of&#xD;
           the preoperative PSMA PET, which led to the indication of salvage lymph node dissection,&#xD;
           is to be investigated in the context of the study and the standardized one- or two-sided&#xD;
           template lymph node dissection. Furthermore, it should be investigated whether there is&#xD;
           a reduction of surgery-associated side effects in patients undergoing unilateral salvage&#xD;
           lymph node dissection. In addition, quality of life and psychological stress of patients&#xD;
           is systematically recorded by means of validated questionnaires. Since salvage lymph&#xD;
           node dissection may also be carried out with the help of currently experimental&#xD;
           preoperative labeling with PSMA ligands for easier intraoperative localization (PSMA&#xD;
           radioguided surgery), a comparison of conventional salvage surgery and the PSMA&#xD;
           radioguided surgery is also planned. However, if applied to patients, PSMA radioguided&#xD;
           surgery is performed outside of the study protocol and is explicitly not part of the&#xD;
           study protocol.&#xD;
&#xD;
      In case there is no complete biochemical response (cBR, PSA &lt;0.2ng / ml) or, after reaching&#xD;
      cBR, a further increase in PSA above 0.2ng / ml threshold is observed after salvage lymph&#xD;
      node dissection, an attempt should be made to localize recurrence disease using PSMA PET.&#xD;
      This should provide indirect information as to whether re-irradiation following salvage lymph&#xD;
      node dissection could be a useful approach and should be investigated in future studies.&#xD;
      However, PSMA PET is recommended in the study, but is optional and therefore to be performed&#xD;
      outside of the study protocol.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 15, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of complete biochemical response</measure>
    <time_frame>24 months</time_frame>
    <description>cBR: PSA &lt;0.2ng / ml after salvage lymph node dissection without adjuvant prostate cancer specific therapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prostate cancer-specific therapy-free survival</measure>
    <time_frame>12 months</time_frame>
    <description>e.g. medicinal, radiotherapy, operative</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">397</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Unilateral lymphnode dissection</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Salvage lymphnode dissection is performed on the PSMA PET positive side, according to template (obturator, iliac external, iliac internal, iliac commun) and possibly including other anatomical pelvic regions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>bilateral Lymphnode dissection</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In addition, a salvage lymphnode dissection is performed on the opposite side with resection of the corresponding fields, which were taken on the PSMA-PET positive side</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Salvage Lymphnode dissection</intervention_name>
    <description>A salvage lymphnode dissection is performed in all study patients (both arms)using standard surgical techniques (openly or DaVinci).In patients who were randomized to the bilateral pelvic lymphnode dissection group, a salvage lymphadenectomy was also performed on the opposite side with resection of the corresponding fields that were removed on the PSMA-PET positive side (th &quot;Blinding&quot; must be guaranteed during pathological assessment)</description>
    <arm_group_label>Unilateral lymphnode dissection</arm_group_label>
    <arm_group_label>bilateral Lymphnode dissection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients in good general condition with life expectancy&gt; 10 years&#xD;
&#xD;
          -  Hormone-sensitive prostate cancer recurrence after radical prostatectomy (patients&#xD;
             with status post salvage prostatectomy may be included; salvage radiotherapy for&#xD;
             prostate fossa and / or pelvic lymph drainage after radical prostatectomy is not an&#xD;
             exclusion criterion)&#xD;
&#xD;
          -  Unilateral detection of â‰¤ 3 PSMA PET positive lymph node metastases in the pelvis (up&#xD;
             ot origin of the inferior mesenteric artery)&#xD;
&#xD;
          -  PSA at the time of PSMA PET imaging &lt;4 ng / ml&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Contraindication for surgery or bilateral salvage lymph node dissection&#xD;
&#xD;
          -  Suspected prostate cancer recurrence in the prostate fossa (local recurrence) or&#xD;
             extrapelvic metastasis on PSMA PET imaging&#xD;
&#xD;
          -  Date of PSMA PET examination &gt; 4 months prior to salvage lymph node dissection&#xD;
&#xD;
          -  Hormone therapy within 6 months prior to study enrollment&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Tobias Maurer, PD Dr.</last_name>
    <phone>+49 (0) 40 7410 53115</phone>
    <email>t.maurer@uke.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Martini-Klinik am UKE GmbH</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Markus Graefen, Professor</last_name>
      <phone>+4904741051300</phone>
      <email>graefen@uke.de</email>
    </contact>
    <contact_backup>
      <last_name>Anke Renter</last_name>
      <phone>+49047410533115</phone>
      <email>renter@uke.de</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>February 12, 2020</study_first_submitted>
  <study_first_submitted_qc>February 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 17, 2020</study_first_posted>
  <last_update_submitted>April 14, 2021</last_update_submitted>
  <last_update_submitted_qc>April 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>prostate cancer recurrence</keyword>
  <keyword>salvage lymph node dissection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

